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RETROVIRAL ANTIBODIES IN WILD-CAUGHT NEW WORLD PRIMATES. 
Lisa S. Ragen and Francis L. Black. Department of 
Epidemiology and Public Health, Yale University School of 
Medicine, New Haven, CT. 
Sera from 387 wild-caught Brazilian monkeys were screened 
for HIV-1 and related retroviral antibodies. Serological 
reactions with HIV-1 ELISA were observed in 4.6% of these 
New World primates. The reactions were confirmed by 
partial reactions in HIV-1 Western Blot and HIV-2 Radio 
Immune Precipitation Assays. The positive sera came from 
animals caught in diverse parts of the Amazon Basin and 
from five of eight species. These results suggest that 
one or more viruses related to HIV-1 may be indigenous to 
South America. Isolation of the virus or viruses is 
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INTRODUCTION AND LITERATURE REVIEW 
Introduction 
Following the 1983 discovery of the T-cell 
tropic retrovirus. Human Immune Deficiency Virus type 1 
(HIV-1),1 presumed to be the cause of the Acquired Immune 
Deficiency Syndrome (AIDS) in humans,2 there has been a 
widespread search for related retroviruses throughout the 
world. Much of this research has focused on Africa where 
infection with retroviruses occurs both in human and non¬ 
human primates. Recent studies report the presence of 
antibodies to HIV-1 in indigenous South American people in 
Venezuala3 and Brazil.4 There is no previous evidence, 
however, for the existence of HIV-1 or a related 
retroviral infection in New World primates.5'6 This study 
of sera from 387 Brazilian monkeys was designed to screen 
a large number of New World primates for HIV-1 and related 
retroviral antibodies. 
The Retrovirus Family 
The Retroviridae family is composed of three 
subfamilies of animal viruses that contain an RNA- 
dependent DNA polymerase. The viruses use this unique 
viral enzyme known as reverse transcriptase to copy their 
RNA genome into DNA. The retrovirus virions are 80 to 
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130 nm in diameter and consist of an inner electron dense 
core surrounded by an outer envelope. This lipid- 
containing envelope forms when the virus buds from the 
plasma membrane of its host cell. All retroviruses 
require three basic genes for replication: gag for the 
viral internal core proteins, pol, the polymerase or 
reverse transcriptase gene, and env for the envelope 
glycoprotein. The 5' to 3' order in all retroviruses is 
gag-pol-env. Long terminal repeat (LTR) sequences on both 
ends of the virus genome code for transcription-initiation 
sequences. Other control genes exist at variable sites on 
the genome. 
In spite of a gross morphogenesis common to 
all retroviruses, there are differences in biochemical, 
fine morphological, and biological properties which allow 
division into three subfamilies: Lentivirinae, 
Oncovirinae, and Spumavirinae. Lentiviruses are 
exemplified by the prototype Visna virus, known to cause a 
slow inflammatory disease in sheep and an ability to kill 
cells in vitro. The oncoviruses, further divided into four 
intercisternal types A, B, C, and D, have a potential for 
oncogenic action. Spumaviruses cause inapparent disease 




Retroviruses in Humans 
Prior to the discovery of HIV-1, the only 
known human retroviruses were Human T-cell Leukemia Virus 
type 1 (HTLV-I) and type 2 (HTLV-II), both with oncogenic 
potential and similar to type C oncoviruses. HTLV-I is 
strongly associated with adult T-cell leukemias.8,9 
HTLV-II was first detected and isolated in cultured cells 
from a patient with hairy cell leukemia.10 In 1986, the 
discovery of two more human retroviruses was announced.11 
Human Immune Deficiency Virus, type 2 (HIV-2, previously 
named Lymphadenopathy Associated Virus-II, LAV-II) was 
originally isolated from two West African AIDS patients.12 
Human T-cell Lymphotropic Virus, type IV (HTLV-IV) was 
reported to be found in healthy Senegalese people and 
appeared not to be associated with immune 
deficiency.13*14,15 Subsequent molecular cloning of 
HTLV-IV revealed it to be nearly identical to the Simian 
Immunodeficiency Virus (SIV) to be discussed below;16 
HTLV-IV is now believed to be a laboratory contaminant of 
one of the original SIV isolates.17,18 HIV-2 infection, 
however, is prevalant in West Africa. HIV-2 has served as 
a source of antigen for extensive human surveys that | 
revealed high antibody prevalence in western Sub-Saharan 
Africa. 
Molecular cloning permitted sequence 
analysis of HIV-2 that demonstrated its existence as a 
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unique retrovirus related to but distinct from HIV-1.19 
Epidemiologic investigation in West Africa suggests that 
HIV-2 can cause AIDS independent of HIV-120’21; but 
comparison of HIV-1 and HIV-2 seropositive populations in 
Africa demonstrate that HIV-2 is much slower to progress 
from inapparent infection to generalized lymphadenopathy 
or AIDS Related Complex (ARC) in HIV-2 infected people.22 
Further seroepidemiologic studies confirm differences in 
the morbidity rates of HIV-1 and HIV-2. HIV-1 
seropositivity, highly correlated with AIDS or AIDS-like 
syndromes, is seen at high rates in Central Africa, but is 
rare in West Africa. HIV-2, on the other hand, is 
primarily seen in West African countries and is less 
frequently associated with AIDS.23*24 
Pending further investigation of HIV-2, 
HIV-1 remains the virus of major concern behind the AIDS 
epidemic; its classification, structure, and relation to 
other retroviruses are of paramount importance in the 
search for AIDS vaccines.26 It was initially thought that 
HIV-1 would prove to be most closely linked to HTLV-1 and 
HTLV-2 and thereby belong to the oncovirus subfamily. 
These three retroviruses have many important properties in 
common. They are human, exogenous, infectious 
retroviruses isolated from mature T-cells with a 
particular T4 tropism. They induce syncytial formation 
and impair T-cell function in vitro and cause 
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immunosuppression in vivo. The major core proteins are of 
similar size and there are stretches of nucleotide 
sequence homology most noticeable in the qaq-pol region 
and LTRs.2*26 There also appears to be serological cross¬ 
reaction between HTLV-1 and HIV-1.27 
Upon discovery of the HIV-1 nucleotide 
sequence,28’29,30 and that of Visna virus,31 however, it 
appears that HIV-1 is a member of the Lentivirus 
subfamily.31’32,33 Similarities between Visna Virus and 
HIV-1 include a shared central region between pol and env 
not found in other retroviruses32 and remarkable 
nucleotide sequence homology particularly strong in the 
gag-pol region.33 HIV-1 and lentiviruses are unique among 
retroviruses in possessing high molecular weight envelope 
proteins.34 In addition, at least two members of the 
Lentivirus subfamily, Visna virus36 and Equine Infectious 
Anemia virus (EIAV),36 show antigenic variation during 
persistent infection. Genetic variability has been found 
in HIV-1 as well,13’37,38’39 but it is not yet clear if 
this diversity of genomic expression is a lentivirus sub¬ 
family trait. 
Knowledge of the genetic sequences of human 
retroviruses has shed light on their protein structures 
and actions. HIV-1 has a complex genome structure which 
codes for at least six major proteins or polyprotein 
precursors as depicted schematically in Figure l.40*41 

There are also four or five genes coding for non- 
structural proteins, two of which are located between pol 
6 
and env genes.42 The gag gene codes for a polyprotein 
with a molecular mass of about 55 kilodaltons (kD). This 
polypeptide, p55, is a precursor of two core proteins, pl8 
and p25. The pol gene codes for the reverse 
transcriptase, endonuclease, and protease actions of the 
virus represented by p68 and p34. The third and fourth 
genes are called sor and tat, for short open reading frame 
and transactivation of transcription respectively. Tat 
may activate transcription of viral genes and regulate 
transcription of some cellular genes;28 it appears to be 
necessary for cell death.43 The primary HIV-1 envelope 
gene product is a 160 kD glycoprotein that is processed to 
gpllO and gp41. Gp41 is the transmembrane protein which 
joins the envelope to the virus core.44 Nearly all AIDS 
patients have antibodies to gpllO34 in addition to most of 
the other major structural proteins, both core and 
envelope. The final area before the 3' LTR is designated 
orf for open reading frame. 
There is substantial cross-reactivity 
between many of the viral antigens of HIV-1 and HIV-2.24 
Western Blot (WB) or Radio Immune Precipitation Assay 
(RIPA) confirmation has been used to distinguish between 
these two viruses based on the thought that serological 
cross-reactivity was primarily restricted to the major 
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core proteins. For example, HIV-2 env glycoproteins were 
not immunoprecipitated by HIV-1 positive sera in one 
study.19 Recent evidence, however, suggests that HIV-1 
and HIV-2 cross reactivity in WB may be far more common 
than originally believed.45 Gpl40, p36, p26, and pl6 are 
the major HIV-2 proteins identified in RIPA and correspond 
to HIV-1 proteins gpllO, p34, p25, and pl8. Although 
their basic structure is the same,42 the genome of HIV-2 
is less than 50% homologous with that of HIV-1. 
Comparison of sequences reveals a 52% homology in the gag 
region, 55% in pol, and 35% in env for a weighted average 
of 43%.46 
Retroviruses in Primates 
It is now recognized that T-lymphotropic 
retroviruses closely related to HIV-2 infect Old World 
non-human primates. To date, there are no reports of 
antibodies to any of the HTLV or HIV retroviruses in New 
World primates. In one study, fifty-five sera from four 
families of New World monkeys were found seronegative for 
HTLV-1,5 and in another survey, thirty-five sera from two 
New World primate families were negative.6 A Medline 
search found no evidence of simian AIDS infection in New 
World primates.47 As of late 1987, Hayami et al report 
the absence of HIV-1 or related antibodies in their 
surveys of New World monkey sera.48 Two retroviruses have 
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been previously isolated, however, from the New World 
Saimiri scieureus: Squirrel Monkey Retrovirus (SMRV) and 
M534. As these are grouped under the Oncovirus type D 
heading,49’60 there appear to be no known lentiviruses in 
New World primates. 
Serologic studies in Old World primates, 
however, do show evidence for HIV-related retroviral 
infection in several species. Antibodies to HTLV-1 in 
non-human primates were first discovered in Japanese 
macaques.61 They have since been identified in a variety 
of species of Old World primates in Africa and Asia.6*6 
Species of the genus Macaca have been thoroughly studied; 
in a survey of 703 sera from ten species of monkeys, the 
frequencies of seropositive apparently healthy macaques 
ranged from 10 to 50%.6 The genus Cercopithecinae has 
also received much attention; one study found 32/53 
healthy Cercopithecus aethiops, African Green Monkeys, to 
be HTLV-1 antibody positive.6 In addition to studies in 
healthy monkeys, HTLV-1 antibodies have been found in 
association with malignant lymphoma or lymphoproliferative 
disease in captive macaques. One study found 11/13 
macaques with naturally occurring lymphoid neoplasms to be 
HTLV-1 antibody positive in contrast to 7 seropositive of 
95 healthy macaques.62 
A virus similar but not identical to HTLV-1 
has been isolated from HTLV-1 seropositive primates and is 
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known as Simian T-cell Lymphotropic Virus (STLV).53,54 
This monkey virus has the same genome structure, LTR-qaq- 
pol-env-pX-LTR, as the human retroviruses. Analysis of 
the env-pX-LTR region shows a 90% homology between STLV 
and HTLV-1.5 5 
More recent studies in Old World primates 
have isolated a new simian retrovirus similar to HIV-1 and 
HIV-2. Now named Simian Immune Deficiency Virus (SIV- 
previously referred to as Simian T-cell Lymphotropic Virus 
type 3, STLV-III), this retrovirus has been found in 
macaques,56,67 African Green Monkeys,58 sooty mangabeys,89 
and mandrills.48 SIV was initially found to be related to 
HIV-1 and HIV-2 by the antigenic properties of its 
proteins and by its biological properties including 
cytopathic effect and tropism for T4 cells.56•57■8 8 * 8 9 It 
appears to be associated with immune deficiencies similar 
to AIDS in the macaques,58,59,60 but not in the African 
Green Monkeys60 or mangabeys.59,60 SIV infection can even 
transmit immune deficiencies in macaques; SIV„AC was 
inoculated into six healthy rhesus monkeys producing an 
AIDS-like disease in four of them.61 Figure 2 illustrates 
the evolutionary relationships of the Old and New World 
primates with SIV isolates located according to the genus 
I 
I 




SIV is clearly related to HIV-1 and HIV-2. 
RIPA analysis of SIVMAC demonstrates SIV specific proteins 
of 160, 120, 55, and 24 kD similar in size to the HIV-1 
major gag and env proteins.5® Subsequent nucleotide 
sequence analysis of SIVAOM verified that it has the same 
general gene structure as HIV-1 except for truncation of 
the two transmembrane glycoproteins.64 Like HIV-1 and 
HIV-2, SIVAOH contains the functional transactivator tat 
gene.66 Sera from sooty mangabey monkeys and from SIV9H 
inoculated rhesus monkeys showed strong reactivity to the 
major viral antigens of HIV-2. Likewise, human HIV-2 
positive sera reacts specifically with the core and 
envelope SIVsn antigens.66 
Nucleotide sequence analysis of SIV reveals 
that SIV is more closely related to HIV-2 than to 
HIV-1.46*67*6® When the SIV env gene is compared to the 
env gene of several HIV-1 isolates, the sequence shows 35- 
45% homology; SIV and HIV-2 homology in the same region is 
approximately 70%.6® Other areas correlate for an overall 
72% homology between SIVAO„ and HIV-2 and a 43% homology 
between SIVAO„ and HIV-1.44 Studies of SIVnAC reveal 
comparable sequence homology percentages wih HIV-1 and 
HIV-2. For example, the SIVnAC pol gene is 83.6% 
homologous with HIV-2 and 59% with HIV-1, again suggesting 
a closer relationship between SIV and HIV-2.67 
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Evolution of Retroviruses 
Such comparisons of sequence homology have 
allowed investigators to speculate on the evolution of 
retroviruses. Genealogical trees have been constructed 
based on knowledge of genetic data, morphological 
characteristics, and protein cross-reactivity. All agree 
on a common progenitor for the retroviruses with early 
division between the oncoviruses and lentiviruses. Among 
the lentiviruses, it appears that HIV-1, HIV-2, and SIV 
diverged more recently than did Visna and the other 
ungulate lentiviruses, EIAV and Caprine Arthritis 
Encephalitis virus (CAEV). Similarly, HIV-2 and SIV 
diverged more recently than HIV-1 and HIV-2.24 Figure 3 
presents a retroviral family tree consistent with current 
information. 2 6*31*32*6B*69 
The presence of similar retroviruses in 
humans and primates has led to controversy over the 
possibility of interspecies transmission. The unique 
distribution of HTLV-1 led Gallo et al to form an 
intriguing hypothesis; they described the origin of HTLV-1 
infection in Africans from contact with infected Old World 
primates and the subsequent spread of HTLV-1 infection to 
Japan via Portugese seamen in the 16th century.70 With 
more information, this theory appears to have been 
discounted.71 After the characterization of STLV-1, 
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Komuro et al state that "the ancestor virus infected 
simians and humans independently, and has been preserved 
in their species with slight modification during their 
developmental process. Transmission of the viruses from 
monkeys to humans, if in fact it occurred, could not have 
been a recent event."64 In 1987, Hayami, a member of the 
same research group, extended this opinion to HIV-1, 
HIV-2, and SIV; he acknowledges a common ancestor in the 
distant past, but believes that they evolved independently 
in their respective species.4® Kanki et al agree and 
state that the greater similarity between different HIV-2 
isolates than between HIV-2 isolates and SIVAOH is 
compatible with their development in different species.24 
Retroviruses in South America 
Regardless of questions concerning the 
precise connection between HIV-1, HIV-2, and SIV, there is 
no doubt that they are closely interrelated. The recent 
discovery of antibodies to HIV-1 and related retroviruses 
in indigenous South American people raises the possibility 
of HIV-1 or related retroviral infection in South American 
monkeys. The South American findings include the presence 
of HIV-1 or related retroviral antibodies in Venezualan,3 
and Brazilian Indians.4 In Venezuala, 9/224 isolated 
Amazon Indians were found positive for HIV-1 antibodies by 
Immunoflouresence, WB, and RIPA.3 In 17/25 isolated South 
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American Indian tribes, 91/2441 serum specimens reacted 
positively in HIV-1 ELISA tests. All of twelve HIV ELISA 
positive sera reacted in HIV-1 WB, but only one with the 
characteristic pattern of bands in HIV-1 infection.4 
As mentioned earlier, however, there is no 
previous evidence for the presence of HIV-1 or related 
retroviral infection in New World primates. Given the 
existence of SIV in Old World primates and its close 
relationship to human retroviruses, the discovery of HIV-1 
infection in indigenous South American people provided the 
impetus for this study of 387 South American monkey sera. 
These monkey sera were screened for antibodies to HIV-1 on 
the hypothesis that an HIV-1 related retroviral infection 
exists in New World primates. 
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MATERIALS AND METHODS 
Specimens 
The specimens tested were from two 
collections of wild-caught primate sera in Brazil. 211 
specimens were from Instituto Evandro Chagas in Belem, 
Brazil. These specimens were collected from 1970 to 1985 
from the Amazon region and include nine genera distributed 
as follows: Alouatta (70), Aotes (7), Ateles (17), 
Callicebus (1), Cebus (82), Chiropotes (21), Pithecia (1), 
Saguinus (8), and Saimiri (4). 176 serum samples were 
from a collection at the University of Para. These 
specimens are all Alouatta and were collected from the 
Tucurui reservoir area on the Tocantins river in 1983. 
Figure 4 illustrates the location of the collection sites. 
All monkeys were apparently healthy at the 
time of capture, though not thoroughly examined. Between 
collection and testing the sera were stored at -40°C, but 





The initial screening of 387 primate sera 
was conducted at Instituto Evandro Chagas in Belem, Brazil 
using the Electronucleonics ELISA kit. In this test 
purified inactivated HIV-1 from the H9 cell line is 
adsorbed onto wells of a microassay plate. Any HIV-1 
antibodies in sera samples form stable complexes with 
HIV-1 antigens on the plate. Goat anti-human IgG labeled 
with peroxidase binds to the antigen-antibody complex and 
color develops in positive wells after the addition of an 
enzyme substrate.72 This kit was used according to 
manufacturer's instructions with the replacement of 
peroxidase-conjugated anti-human IgG by peroxidase- 
conjugated Protein A. 
Protein A is a S. aureus cell wall protein 
which binds to the F0 portion of immunoglobulins of nearly 
all mammalian species. The Protein A ELISA protocol was 
established on the basis of three procedures: 
Immunodiffusion, HIV-1 ELISA comparison tests between 
Protein A and anti-human IgG, and Whittaker M.A. 
Bioproducts MEASLELISA comparison tests between Protein A 
and anti-human IgG on New World monkey sera. The 
immunodiffusion demonstrated only partial cross-reaction 
between anti-human IgG and the primate sera. The HIV-1 
ELISA comparison tests showed greater reproducibility with 
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Protein A than with anti-human IgG. The MEASLELISA tests, 
however, were the most conclusive in the selection of 
Protein A over the Electronucleonics conjugate. 
MEASLELISA tests were run on pre-vaccination and three 
weeks post-vaccination New World monkeys given the measles 
vaccine. With hemagglutination inhibition as a reference, 
the Protein A results proved to be far more accurate than 
the anti-human IgG results. (See Results; Protein A vs. 
anti-human IgG.) The Protein A was used at a dilution of 
1:12000 to correlate closely with the given control values 
of the Electronucleonics kit. 
The Burroughs-Wellcome "Wellcozyme" 
competitive ELISA test was also used in the initial 
screening process on 78 sera previously tested with the 
Electronucleonics kit. The Wellcozyme test microwells are 
coated with inactivated HIV-1 antigen that has bound to 
purified HIV-1 antibodies previously attached to the 
wells. Sera samples incubate in the wells with 
peroxidase-conjugated anti-HIV-1; antibodies to HIV-1 in 
the samples compete with the conjugate for binding to the 
HIV-1 antigen. The amount of color in each well after the 
addition of the enzyme substrate is inversely proportional 
to the concentration of HIV-1 antibody in the sample.73 
It is said by the manufacturer to be more antigen specific 
than the ELISA test. The Wellcozyme kit was used 
according to manufacturer's instructions. 
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2) Western Blot 
Western Blot tests were run to confirm 
positive direct ELISA results. Diagnostics Pasteur WB kit 
was used at Institut Pasteur according to manufacturer's 
instructions. Inactivated HIV-1 viral proteins were 
separated by polyacrylamide gel electrophoresis and 
transferred onto a nitrocellulose sheet. Nitrocellulose 
strips were saturated with non-fat milk to prevent non¬ 
specific reactions and then incubated with serum 
specimens. HIV-1 antibodies bind to viral antigens and 
are detected by the addition of peroxidase-labelled sheep 
anti-human IgG and enzyme substrate. Bands stained 
specifically for known viral proteins allow determination 
of antibodies.40,41 
3) Radio Immune Precipitation Assay 
Sera found positive for at least one HIV-1 
protein on WB were further tested for HIV-1 and HIV-2 
specific proteins by the RIPA procedure as developed at 
Institut Pasteur. HIV-1 and HIV-2 infected cells were 
labelled with 36S cysteine. These cells were exposed to 
3 6 S cysteine (200uCi/ml) by incubation overnight at 37 C. 
Clarified supernatant was centrifuged at 100,000g for 100 
minutes at 4°C. The pellet was lysed in a RIPA buffer 
containing 50mM TRIS-HC1 pH 7.4, 150mM NaCl, ImM EDTA, 
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1% Triton X-100, 0.1% sodium deoxycholate, 0.1% sodium 
lauryl sulfate. The lysate was diluted to yield SBS 
antigen at 100,000 cpm. 50ul of the diluted virus lysate 
was incubated overnight with 5ul of each serum sample at 
4°C. Immune complexes were adsorbed on Protein A- 
Sepharose CL-4B and analyzed by electrophoresis on sodium 
dodecyl sulfate-polyacrylamide gels (SDS-PAGE). Gels were 
dried and exposed to x-ray films in order to visualize the 
radioactive proteins. 
Evaluation of Results 
ELISA results were judged to be negative, 
borderline, or positive. As the initial screening process 
was designed to survey a large number of possible positive 
specimens, borderline positive results were retested as 
were all sera meeting the manufacturer's criteria for 
positivity. The term ELISA positive is used here to refer 
to sera that were positive in one assay and positive or at 
least borderline in a repeat test. 
WB results were evaluated specifically for 
each retroviral protein and not for HIV-1 presence or 
absence. The criteria for HIV-1 positive WB results in 
humans vary, as mentioned in the Discussion. Moreover, 
the goal of this study was the detection of serological 
evidence of HIV-1 or related retroviral infection and not 
only HIV-1 itself. Therefore, the presence of any HIV-1 
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proteins was considered significant. 
RIPA results were also recorded by presence 




Protein A vs. anti-human IgG 
The MEASLELISA and Hemagglutination 
Inhibition (HI) tests run on the monkey sera drawn prior 
to vaccination were conclusively negative. Three weeks 
after the vaccination of the monkeys, the sera were 
retested. Using HI as a reference. Protein A and anti¬ 
human IgG were compared in the MEASLELISA test. HI showed 
the post-vaccination sera to be markedly positive in all 
monkey sera: >1 : 256. The anti-human IgG results showed 
the post-vaccination sera to be, on average, 10.7% of the 
positive control whereas the Protein A tested sera were 
58% of the positive control. 
ELISA Reactions 
Eighteen of 387 primate sera screened by 
HIV-1 ELISA with Protein A tested positive in two separate 
tests or positive and borderline in two separate tests. 
The distribution by genus is shown in Table 1. Five of 
the positive sera were from the Tocantins river Alouatta 
collection at the University of Para. The remaining 13 
were from the collection at Instituto Evandro Chagas and 
were from a wide distribution of locations within the 
Amazon. 
The indirect ELISA results were uniformly 
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negative for the 78 sera tested. These 78 include all 18 
sera found positive or reactive by HIV-1 direct ELISA. 
Western Blot Results 
Thirty sera including 10 of the 18 
originally positive by HIV-1 ELISA were tested by HIV-1 
Western Blot. The sera supply of 8 originally positive 
samples had been depleted in previous tests. 12 sera were 
positive for at least one major protein including four of 
the eight ELISA positive sera. Figure 5 is a photograph of 
6 positive reactions. Individual results by genus are 
shown in Table 2 for these 6 specimens. The negative 
control shown in Figure 5 had a trace positive reaction at 
pl8. Results as interpreted in Table 2 with trace, +, or 
++ take this negative control into account. Eighteen sera 
were completely negative or had trace bands only. 
RIPA Results 
Seventeen sera, including the 12 found 
positive for at least one HIV-1 protein on WB, were tested 
by RIPA for HIV-1. No sera were found positive for HIV-1 
proteins. Twenty-eight sera were tested for HIV-2 
antibodies; one sera, PR1682, from a Cebus monkey, showed 
evidence of a glycoprotein between gpllO and gpl60 and a 
band at p26. Figure 6 is a photograph of the HIV-2 RIPA 
results. It should be noted that intensity of bands is 

22 
key to determining positive results in this RIPA test. 
The faint bands on the negative control are similar in 





Sources of error must be considered before 
the results of this study can be discussed. The false 
positive (FP) rate is of much publicized concern in the 
use of HIV-1 ELISA as a screening test.74 Six commercial 
HIV-1 ELISA kits, not including Electronucleonics used 
here, were found to have FP rates from 0 to 0.42%.76 This 
rate is low when the purpose for which the tests were 
developed is taken into consideration. As they were 
produced in order to screen donated blood for HIV-1 
antibodies, the system is overloaded with antigen to 
enhance sensitivity at the expense of specificity.76 
In addition, there are certain illnesses 
which are known to predispose sera to FP reactions: 
autoimmune diseases with circulating antibodies to HLA, 
nuclear, and other cellular antigens, acute viral diseases 
such as cytomegalovirus and Epstein-Barr infections with 
cross-reacting antibodies, immune dysfunction associated 
with liver disease, lymphoproliferative disease and 
multiple myeloma with hypergammaglobulinemia, adult T-cell 
leukemia with cross-reactive HTLV-1 antibodies, and 
recurrent malaria with anti-lymphocyte, anti-nuclear, and 
other auto-antibodies.41,76'77 Certain healthy people are 
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also susceptible to FP HIV-1 ELISA reactions including 
people with anti-HLA-DR4 such as multiparous women or 
patients with transfusion-induced antibodies specific for 
the class II major histocompatibility antigens present in 
the large scale manufacture of HIV-1.76*78 Finally, heat 
treatment, prolonged storage of sera, and procedural 
errors while using the ELISA kits may lead both to FP and 
false negative (FN) reactions.41 
Other FN reactions are found in AIDS 
patients who have a decreased antibody titer in late stage 
disease and in pre-AIDS patients who do not have 
detectable antibody for six weeks after the initial 
infection.41 ELISA FN reactions have also been reported 
in patients taking immunosuppressive drugs who are found 
to be HIV-1 positive by confirmatory tests.79 
While most of these examples pertain 
specifically to humans, they nonetheless illustrate the 
extent of FP reactions in commercial ELISA kits and 
justify the use of confirmatory tests on all HIV-1 ELISA 
positive sera. This study includes the additional 
complicating factors of using monkey sera and Protein A, 
so the frequency of FP reactions may be higher. The 
expected FP rate is not possible to calculate, however, 
because of these unknowns as well as variations in FP 
rates noted even among different runs of the same 
manufacturer's kit.80 With the information concerning 
ELISA FPs in mind, the initial design of this study 
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followed standard procedure for human studies in that all 
initially positive ELISA sera were retested and only those 
reactive in both tests were then confirmed by Western 
Blotting. 
WB is the most common confirmatory test for 
the presence of HIV-1 antibody and the standard against 
which other techniques are compared. It has been recently 
recognized, however, that Western Blots have also produced 
FP results; differences in interpretation and a lack of 
standardization in criteria for positivity and negativity 
account for many of these.74 Biberfield et al describe 
the appearance of bands for p24 and p55 in HIV-1 negative 
individuals and suggest that this phenomenon is due to 
cross-reactions with normal cell constituents such as 
ribonucleproteins or to the presence of other human 
retroviruses.81 Couroce et al found eight sera with the 
same p25-p55 pattern and 23 with pl8 and p55 in screening 
151,667 blood donors. These 31 sera were the only both 
HIV-1 and HIV-2 RIPA negative specimens out of their 130 
WB positive sera and were therefore thought to be 
negative.82 Similar atypical WB results have been 
reported by Dock et al who, in contrast, believe the 
unusual WB reactivity is directed against retroviral core 
proteins.83 These examples lend credence to the belief 




Others (Roy et al) stress caution in 
interpreting WB for HIV-1 while describing a woman with 
positive ELISA and positive WB who was found to be HIV-1 
negative by a different ELISA test and by negative 
isolation on a later occasion; they traced the FP to a 
reactivity to antigens from the cultured human cells in 
which the HIV-1 had grown.84 A study of commercial 
laboratories by the U.S. Army found 85-100% accuracy in 
HIV-1 WB. Four out of five labs reported at least one FP 
result out of 15 specimens; all FPs were on different 
normal specimens leading the authors (Burke et al) to 
believe the errors were due to technique and not to 
intrinsic biologic properties of the sera.85 
The WB FP controversy primarily concerns the 
lack of agreement on which proteins are necessary to 
diagnose HIV-1 infection. This study, however, was not 
limited to HIV-1 infection, but concerned instead with the 
presence of HIV-1 or any related retrovirus. Western Blot 
results were reported by protein, not by HIV-1 positivity 
or negativity, thus avoiding one of the sources of HIV-1 
FP reports. The partial positive results reported here do 
not satisfy the current criteria for HIV-1 infection in 
humans, but positive results may still be significant. 
Moreover, all sera positive by WB for at least one major 
HIV-1 protein were tested for the presence of both HIV-1 
and HIV-2 by RIPA, an acknowledged confirmatory test. The 
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RIPA offers the lowest chance of false reactions in that 
it does not depend on anti-human sera and yet resolves 
reactions to individual proteins. 
With the above information on possible 
sources of error in mind, the results may now be 
discussed. In the initial tests, 4.6% of the New World 
primate sera tested here were initially positive by HIV-1 
direct ELISA (Table 1). These results were confirmed in 
repeat tests. Five of these specimens were from the 
Tocantins Alouatta collection and the other 13 from widely 
distributed locations (Oriximina, Santar^m, Goias, and the 
Tucurui reservoir area) and several species. The 
reproducibility of the tests and subsequent partial 
confirmation by WB and RIPA indicate that these reactions 
are more than an artifact of chance, in spite of the 
uniformly negative Wellcome kit ELISA results. Negative 
results by Wellcozyme may be explained by the fact that 
this kit is a competitive ELISA test and is consistently 
more specific and less prone to register reactions with 
cross-reacting antibodies than the direct ELISA. It has 
been suggested that partly cross-reacting antibodies may 
not be able to compete with simultaneously added HIV-1 
antibodies. This theory has been used to explain HTLV-IV 
antibody positive sera found negative by the HIV-1 
Wellcome kit.86 
The direct ELISA results are to be 
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considered while remembering the forementioned study of 
six commercial ELISA kits showing a range of false 
positive reactions of 0 to 0.42%.74 The proportion of 
positive specimens in this study is therefore more than 
ten times that expected of non-specific reactions. The 
most relevant source of FP reactions is chronic malaria 
which occurs in South American monkeys.87 Because the 
sera used had been collected at earlier dates, it was not 
possible to examine matched blood smears for plasmodia. 
More worrisome in evaluating the HIV-1 ELISA is our 
limited experience with protein A in place of the usual 
anti-human reagent. Production of peroxidase conjugated 
sera specific for each simian genus would be needed to 
circumvent this problem. 
The partial positive reactions to HIV-1 and 
HIV-2 virus specific proteins in WB and RIPA suggest the 
possibility that immunity to a retrovirus is present in 
the New World monkeys. Twelve of 30 sera reacted at the 
site of at least one major viral protein band by WB. 
None reacted with all viral proteins. Seventeen sera, 
including those positive by WB, were tested by HIV-1 RIPA, 
but no protein bands were found. Of the 28 sera tested 
for HIV-2 antibodies by RIPA, one, from a Cebus captured 
near IS, 57 W, showed bands at the location of p26 and 
near gpllO. 
If one makes the assumption that the 
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immunizing agent is not HIV-1, the failure to find 
positive rections in the indirect test is not unexpected 
because of the greater specificity of this test as 
described earlier. Similarly, failure to obtain complete 
WB reactions may be due to limited analogy between HIV-1 
and the infecting agent. An additional factor in the WB 
tests may be limited cross reactions between simian and 
human immunoglobulins in their reaction with the goat 
anti-human serum which was not replaced, in this test, 
with Protein A. Although no one monkey serum reacted with 
a full spectrum of viral bands, the diversity of reactions 
in the set of sera was broad enough that it is difficult 
to account for them by postulating reaction with foreign 
antigens in the WB virus preparation. The most prevalant 
reactions are with the gag proteins, as would be expected 
of antibody to an HIV-related virus. 
The RIPA results were similar to the WB test 
in that a full spectrum of viral proteins did not react 
with the monkey sera. In fact, the one positive serum 
gave an atypical pattern. (See Figure 6.) The fact that 
the RIPA HIV-1 tests were entirely negative but that the 
RIPA HIV-2 reacted conforms with the generally more 
central position of HIV-2 in the spectrum of primate 
retroviruses. 
This study provides suggestive evidence that 
one or more Lentiviruses is broadly distributed in New 
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World primates. The postulated virus or viruses relate 
more closely to HIV-2 than HIV-1. The current data do not 
permit distinction between the simian agent and the agent 
that elicits HIV antibody in humans living in the same 
general area. Isolation of the virus or viruses is 
necessary to confirm these initial findings. 
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Table 1: HIV-1 ELISA results by Genus 
Genus no. tested no. positive % positive 
Alouatta 246 10 4.1 
Aotes 7 1 14.3 
Ateles 17 3 17.6 
Callicebus 1 0 0 
Cebus 82 3 3.6 
Chiropotes 21 0 0 
Pithecia 1 0 0 
Saimiri 4 0 0 
Saguinus 8 1 12.5 
TOTAL 387 18 4.6 
Table 1: HIV-1 ELISA results by Genus 
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Serum Genus Band mobility in kD for HIV-1 proteins 
PR1009 Alouatta 
pl8 p25 p34 p40 gp41 
+ + tr 
p55 p68 gpllO gpl60 
+ 
PR1682 Cebus + + + 
PR2045 Cebus tr + 
PR2051 Alouatta tr tr 
Ab456 Alouatta + + + 




= trace band present 
= band present 
= band very strong 
Table 2: HIV-1 Protein Specific Antibody Detected 
by Western Blot in 6 New World Primates 
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Figure 1: Schematic representation of HIV-1 genome with 
major protein translation products. 
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Figure 2: Primate Evolutionary Tree 




















Figure 3: Retrovirus Evolutionary Tree 
Abbreviations as in text with the addition of: 
BLV= Bovine Leukemia Virus 
IAP= Intracisternal A Particle 
MMTV= Mouse Mammary Tumor Virus 


















Figure 5: HIV-1 Western Blot tests with primate sera. 
Lanes: 1- positive control; 2- negative control; 
3- PR1069; 4-PR1682; 5-PR2045; 6-PR2051; 7-Ab456; 
8-PR2062. Lane 4 carries serum from the Cebus that 
was RIPA positive. 
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I 2 3 4 5 6 7 3 9 10 II 12 13 14 
Figure 6: HIV-2 RIPA results 
Lanes: 1-11 Alouatta sera; 12-negative control; 
13- positive control; 14- Cebus serum. The location of 
the major viral proteins in the control are thought to 
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